Castle Biosciences IncCSTL
What Castle Biosciences Inc does.
As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, “Castle Biosciences,” the “Company,” “we,” “us” and “our” refer to Castle Biosciences, Inc., a Delaware Corporation.
Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (“BE”), atopic dermatitis (“AD”), uveal melanoma (“UM”).
Since our inception in 2008, it has been our vision to transform disease management by keeping people first: patients, clinicians, employees and investors. This foundational strategy remains the guidepost for the direction of our company and the basis of long-term value creation.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $62.6M | $94.1M | $137.0M | $219.8M | $332.1M | $344.2M |
| Net income | -$10.3M | -$31.3M | -$67.1M | -$57.5M | $18.2M | -$24.2M |
| Free cash flow | $5.1M | -$22.5M | -$47.3M | -$19.2M | $36.5M | $28.3M |
More on CSTL.
- Castle Biosciences Inc summary
- Castle Biosciences Inc financial statements
- Castle Biosciences Inc key metrics
- Castle Biosciences Inc health scores and style box
- Castle Biosciences Inc earnings
- Castle Biosciences Inc dividends
- Castle Biosciences Inc valuation
- Castle Biosciences Inc ownership and insiders
- Castle Biosciences Inc peers
Figures from Castle Biosciences Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.